Loading stock…

Sanofi (SNY) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

SNYSanofi

Revenue FY25$54.7B

GROWTH RATING↗

WEAK29 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+8%6

Revenue, next 1Y-2%2

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+5%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+159%10

EPS growth, FY27E+5%5

EPS growth, FY28E+10%6

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 10%/yr vs revenue 4%/yr), so margins should widen.

WATCH

Revenue grew 8%/yr over the last 3 years; forecasts see it cooling to 4%/yr.

Over five years revenue is set to grow 5%/yr, behind 60% of companies worldwide.4/10

WEAKNESSES

Growth is the weak spot here, trailing 71% of companies worldwide.

Revenue is set to grow 4%/yr over the next 3 years, behind most of the market.3/10

BOTTOM LINE

Margin Expander

Growth is a weak point here: a business that is slowing. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

SNYSanofi

Total return Current38.2%

Price return Current−2.2%

MOMENTUM RATING↗

WEAK15 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-11%2

3-month return-8%4

YTD return-15%3

MID & LONG-TERM▾SCORE

% of 52-week high78%5

1-year return-16%3

3-year return-19%2

5-year return-5%3

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

It's down 16% over the past year, now 22% below its 52-week high. That is a touch behind the market.

Returns sit at the market level over three months (-8%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-19% over three years and -5.1% over five), behind 70% of the market.

The stock is underperforming over the past month (-11%) and so far this year (-15%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Sanofi. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

SNYSanofi

Revenue FY25$54.7B

GROWTH RATING↗

WEAK29 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+8%6

Revenue, next 1Y-2%2

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+5%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+159%10

EPS growth, FY27E+5%5

EPS growth, FY28E+10%6

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 10%/yr vs revenue 4%/yr), so margins should widen.

WATCH

Revenue grew 8%/yr over the last 3 years; forecasts see it cooling to 4%/yr.

Over five years revenue is set to grow 5%/yr, behind 60% of companies worldwide.4/10

WEAKNESSES

Growth is the weak spot here, trailing 71% of companies worldwide.

Revenue is set to grow 4%/yr over the next 3 years, behind most of the market.3/10

BOTTOM LINE

Margin Expander

Growth is a weak point here: a business that is slowing. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

SNYSanofi

Total return Current38.2%

Price return Current−2.2%

MOMENTUM RATING↗

WEAK15 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-11%2

3-month return-8%4

YTD return-15%3

MID & LONG-TERM▾SCORE

% of 52-week high78%5

1-year return-16%3

3-year return-19%2

5-year return-5%3

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

It's down 16% over the past year, now 22% below its 52-week high. That is a touch behind the market.

Returns sit at the market level over three months (-8%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-19% over three years and -5.1% over five), behind 70% of the market.

The stock is underperforming over the past month (-11%) and so far this year (-15%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Sanofi. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Sanofi

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on Sanofi. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on Sanofi. Get the full investment case.

Premium